Figure 4.

(A) Suvorexant is the first approved drug under DORA. According to the dose-response non-linear curve, at 20 mg, the subjects scored the highest on the DSST scale, and the incidence of motor vehicle driving violations/accidents was the lowest. At doses below 20 mg, the subjects had better information processing, attention, and psychomotor abilities. The diurnal function of the subjects in the suvorexant group decreased significantly after taking a dose of more than 20 mg. It was concluded that the maximum dose of suvorexant should not be more than 20 mg, which was consistent with the recommended doses of 5, 10, 15, and 20 mg in the guidelines. The sleep result seems to have little relationship with the dose. With the increase in dose, LPS decreases, and TST prolongs. SE is lower when it is <30 mg, then SE increases. (B) In the Almorexant group, the subjects' alertness scores were higher at 10 mg to 30 mg and reached the highest alertness at 30 mg, while when the dose was >30 mg, the alertness gradually decreased. In addition, the reaction time decreased with the increase in dose. The dose did not affect the word memory score and body swing amplitude. NAW and WASO showed an upward trend before 30 mg and reached the highest point at 30 mg.